MRD | Blood Cancers Today

MRD

Kerri FitzgeraldAcute Lymphoblastic Leukemia | November 16, 2022

Aaron Logan, MD, PhD, and Elias Jabbour, MD, discussed whether MRD negativity indicates a cure in patients with AML.

Leah LawrencePrint | November 14, 2022

Clinicians who specialize in BPDCN discuss the disease and novel therapeutic approaches to treating patients with BPCDN.

Researchers retrospectively analyzed 580 patients with AML receiving HSCT between January 1999 and November 2020.

Ariel DeMaioMyeloma | November 14, 2022

Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.

Ariel DeMaioChronic Lymphocytic Leukemia | February 2, 2023

Ibrutinib and venetoclax demonstrated superior MRD responses in older/unfit patients with previously untreated CLL.

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer